Aadil Najeed, Senior Resident of Government Medical College Srinagar, shared a post on LinkedIn:
“From Treating Parasites to Targeting Cancer: The Unexpected Antitumor Potential of an Old Drug.
Eflornithine + Lomustine Improves Survival in IDH-Mutant Grade 3 Astrocytoma.
A large international randomized study across 74 sites evaluated eflornithine + lomustine in recurrent glioma.
While the overall population showed no survival difference (OS 23.4 vs 20.3 months), an important signal emerged after applying the updated World Health Organization 2021 CNS classification.
In IDH-mutant grade 3 astrocytoma:
- Overall Survival: 34.9 vs 23.5 months.
- Progression-Free Survival: 15.8 vs 7.2 months.
No benefit was seen in grade 4 disease.
Main toxicities included reversible myelosuppression and hearing impairment, with no new safety signals.
A powerful reminder that molecular classification is reshaping neuro-oncology trials and helping identify patients who truly benefit. Encouraging progress for IDH-mutant astrocytoma.”
Title: STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma
Authors: Howard Colman, Giuseppe Lombardi, Eric T. Wong, Tobias Walbert, Marica Eoli, Andrew B. Lassman, David M. Peereboom, Sani H. Kizilbash, Carlos Kamiya-Matsuoka, Marshall W. Pitz, Roy E. Strowd, Annick Desjardins, Priya Kumthekar, Warren Mason, Alessia Pellerino, Riccardo Soffietti, Nicholas Butowski, Peter A. Forsyth, Mohamed A. Hamza, Peter Hau, Enrico Lallana, Burt Nabors, David Piccioni, Erik J. Uhlmann, Liam C. Welsh, Patrick Y. Wen, Jorg Dietrich, Chao Wang, Victor A. Levin
Read The Full Article
Other articles featuring Aadil Najeed on OncoDaily.